Novel Biomarker Tests Increase Accuracy of Breast and Lung Cancer Diagnoses
January 23rd 2023Andrew McKenzie, PhD, discusses biomarkers to test for in breast and lung cancers, the value of multicancer early detection, and how biomarker testing can better direct targeted treatment across solid tumors.
Read More
CD40-Directed SEA-CD40 Combo Denotes Antitumor Activity in Pancreatic Ductal Adenocarcinoma
January 21st 2023The combination of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab demonstrated early evidence of efficacy in patients with metastatic pancreatic ductal adenocarcinoma, according to updated results from the phase 1 SGNS40-001 study.
Read More
Ibrutinib/Prednisone Provides No CR/PR Benefit vs Placebo/Prednisone in cGVHD
January 18th 2023First-line ibrutinib plus prednisone did not improve response rates compared with placebo plus prednisone in patients with chronic graft-vs-host disease, failing to meet the primary end point of the phase 3 iNTEGRATE trial.
Read More
R-DHAP Regimen Produces Favorable Efficacy in Younger MCL Patients
January 16th 2023R-DHAP plus high-dose cytarabine-containing myeloablative radiochemotherapy conditioning and autologous stem cell transplant demonstrated sustained time to treatment failure and overall survival benefits vs R-CHOP plus standard myeloablative radiochemotherapy and ASCT in patients with mantle cell lymphoma aged 65 years and younger.
Read More
Iyer Shares Ongoing Research in TSC1/2-Mutant Genitourinary Cancers
January 13th 2023Gopa Iyer, MD, explained the rarity of TSC1 and TSC2 mutations in GU cancers, discussed the rationale and design of PRECISION 1, and emphasized the important role next-generation sequencing plays when determining the most effective targeted therapies for patients with GU cancers and other tumor types.
Read More
Brexu-cel Elicits Durable Responses in High-Risk Relapsed/Refractory MCL
January 13th 2023Treatment with brexucabtagene autoleucel produced ongoing responses in patients with mantle cell lymphoma with high-risk disease characteristics, including those with a lower ECOG performance score and tumor burden and less frequent prior use of bridging or platinum therapy.
Read More
Developmental FGFR Inhibitors Are Active in FGFR+ Cholangiocarcinoma and Urothelial Carcinoma
January 6th 2023Mitesh J. Borad, MD, explains how FGFR alterations influence treatment strategies in cholangiocarcinoma and urothelial cancer, discusses the FGFR resistance mechanisms that are prompting further research in this area, and highlights the rationale for the KN-4802 trial.
Read More
Obe-cel Provides Favorable Safety Profile, Expands Potential Treatment Options in B-ALL
January 6th 2023Paul J. Shaughnessy, MD, discusses the unique properties of obecabtagene autoleucel in B-cell acute lymphoblastic leukemia and how findings from the FELIX trial support further research into the benefits of CAR T-cell therapy in patients with hematologic malignancies.
Read More
HAIC-Administered FOLFOX Lengthens DFS and Provides a Tolerable Safety Profile in HCC
January 5th 2023Patients with hepatocellular carcinoma with microvascular invasion who received FOLFOX through hepatic arterial infusion chemotherapy experienced improved disease-free survival rates compared with those who received no adjuvant treatment.
Read More
Glofitamab Plus R-CHOP Displays Tolerable Safety Profile in Treatment-Naïve DLBCL
January 3rd 2023Max S. Topp, MD, highlights the rationale for studying bispecific antibodies in newly diagnosed diffuse large B-cell lymphoma, how the safety profile of glofitamab plus R-CHOP contributes to its potential for outpatient administration, and where future directions with this research may lead.
Read More
DetermaIO Assay Delineates Single-Agent Immunotherapy Benefit in NSCLC
January 3rd 2023David L. Saltman MD, PhD, discusses the unique features of the DetermaIO assay, noted the assay’s applications beyond lung cancer, and emphasized that biomarker combinations potentially have greater predictive benefits than single biomarkers.
Read More
Personalized Immunotherapy Regimens Drive Frontline Melanoma Care
December 29th 2022Claire F. Verschraegen, MD, discusses how nivolumab and ipilimumab fit into the treatment paradigm, poses examples of when treatment-related adverse effects might influence which agents to use, and emphasizes the importance of considering the benefits of immunotherapy.
Read More
Immunotherapy and Targeted Therapy May Represent the Future of Later-line Lung Cancer Treatment
December 27th 2022Konstantinos Leventakos, MD, PhD, discusses the emergence of immunotherapy and lurbinectedin as beneficial treatments in small cell lung cancer, where osimertinib fits into the non–small cell lung cancer treatment paradigm, and more.
Read More
Thrombocytopenia Is Associated With High Levels of Fatigue in Myelofibrosis
December 20th 2022Jeanne M. Palmer, MD, discusses a retrospective analysis of the PERSIST-1 and PAC203 trials, the symptoms that were analyzed across patient populations, and what the findings from this research indicate about the relationship between low platelet counts and symptoms such as fatigue in myelofibrosis.
Read More
Anti-CEACAM5 ADC Could Represent the Next Targeted Therapy in Advanced Nonsquamous NSCLC
December 19th 2022Alexander Spira, MD, PhD, FACP, discusses the rationale for targeting CEACAM5 in NSCLC, how tusamitamab ravtansine could provide encouraging frontline responses in the CEACAM5-positive, nonsquamous population, and enrollment challenges faced by ongoing clinical trials.
Read More
Biomarker Testing Informs Individualized Diagnosis and Treatment of Low- to Intermediate-Risk AML
December 16th 2022Alexander E. Perl, MD, MS, discusses the implications of the updated ELN guidelines, how genetic testing guides treatment in this disease, and ongoing research investigating novel AML targets such as NPM1 mutations or KMT2A translocations.
Read More
Obe-cel Represents a Tolerable CAR T-cell Therapeutic Option in B-ALL
December 14th 2022Elias Jabbour, MD, discusses the current and emerging roles of CAR T-cell therapy in B-ALL, emphasizes the importance of testing patients for MRD when determining CAR T-cell treatment strategies, and highlights how obe-cel, with its favorable safety profile, may address unmet needs related to CAR T-cell toxicities.
Read More
Zilovertamab/Ibrutinib Elicits Durable Responses With Favorable Tolerability in MCL and CLL
December 11th 2022The combination of zilovertamab and ibrutinib resulted in promising clinical response and progression-free survival rates and showcased a tolerable toxicity profile in patients with mantle cell lymphoma and chronic lymphocytic leukemia.
Read More
Resistance Mechanisms Spur Innovative Research in FGFR-Mutant Liver and Bladder Cancer
December 7th 2022Sameek Roychowdhury, MD, PhD, discusses the rationale for targeting FGFR mutations in cholangiocarcinoma and urothelial carcinoma, the potential efficacy of irreversible pan-FGFR inhibitors in these populations, and how continued research in this area may yield more personalized therapeutic approaches for patients with FGFR mutations.
Read More
Antibody-Drug Conjugates Expand HER2+ Breast Cancer Treatment Options
December 5th 2022Erika P. Hamilton, MD, discusses anticipated updates from DESTINY-Breast02 and DESTINY-Breast03 that will be presented at the 2022 San Antonio Breast Cancer Symposium, how trastuzumab emtansine will fit into the armamentarium in light of the efficacy of trastuzumab deruxtecan, and additional data to expect from SABCS regarding ADCs and beyond.
Read More
CG0070/Pembrolizumab Combo Shows Promising Efficacy and Tolerability in NMIBC
November 30th 2022The oncolytic vaccine CG0070 plus pembrolizumab demonstrated encouraging response rates and a tolerable safety profile in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.
Read More
Cabozantinib/Atezolizumab Elicits Durable, Tolerable Clinical Activity in Advanced HNSCC
November 29th 2022The combination of cabozantinib and atezolizumab generated rapid and durable responses in patients with advanced head and neck squamous cell carcinoma who received prior treatment with platinum-based chemotherapy.
Read More
FGFR2 Inhibitor RLY-4008 Appears Durable, Tolerable in Cholangiocarcinoma
November 23rd 2022Suneel Kamath, MD, discusses the current challenges of treating patients with cholangiocarcinoma, the need for more tolerable therapies in this population, and how the significant ORRs and impressive safety profile seen so far with RLY-4008 in the ReFocus trial are indicative of this agent’s efficacy and durability in FGFR2-rearranged cholangiocarcinoma.
Read More
BTK Inhibitor Failure Signals Unmet Need for a Standard of Care in Relapsed/Refractory MCL
November 18th 2022Improved mantle cell lymphoma treatments are necessary for patients who have relapsed on or are refractory to BTK inhibitors, according to findings from SCHOLAR-2, a multicenter, retrospective chart review of European patients with MCL who relapsed following or were intolerant to BTK inhibitors.
Read More